Kivexa

Kivexa

abacavir + lamivudine

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
Concise Prescribing Info
Contents
Abacavir sulfate 600 mg, lamivudine 300 mg
Indications/Uses
Antiretroviral combination therapy for the treatment of HIV infection in adults, adolescent & childn ≥25 kg.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Hypersensitivity reactions observed w/ abacavir. Patients w/ positive HLA-B*5701 status. Increase in wt & in levels of blood lipids & glucose may occur. Pancreatitis. Risk of virological failure when combined w/ tenofovir disoproxil fumarate as once daily regimen. Monitor patients w/ pre-existing liver dysfunction, including chronic active hepatitis. Patients co-infected w/ chronic HBV or HCV. Acute exacerbation of hepatitis in w/drawal of lamivudine may occur; periodic monitoring of both liver function tests & markers of HBV replication is recommended. Mitochondrial dysfunction in HIV-negative infants exposed in utero &/or post-natally to nucleoside analogues (zidovudine). Immune reactivation syndrome. Osteonecrosis. Opportunistic infections. MI. Do not take w/ any other medicinal products containing lamivudine or emtricitabine. Combination of lamivudine w/ cladribine is not recommended. Renal & hepatic impairment. Contains azo colouring agent sunset yellow which may cause allergic reactions. Pregnancy & lactation. Childn <25 kg. Elderly.
Adverse Reactions
Headache; nausea, vomiting, diarrhoea; rash; fatigue, fever. Abacavir: Hypersensitivity; anorexia; lethargy. Lamivudine: Insomnia; cough, nasal symptoms; abdominal pain/cramps; alopecia; arthralgia, muscle disorders; malaise.
Drug Interactions
Abacavir: Altered exposure when co-administered w/ inducers/inhibitors of UGT enzymes. Lamivudine: Increased exposure w/ OCT inhibitors. Do not administer concomitantly w/ other cytidine analogues eg, emtricitabine. Increased AUC w/ co-trimoxazole. Potential risk of cladribine loss of efficacy. Occasionally methadone re-titration may be required. Decreased AUC & Cmax w/ sorbitol soln (3.2 g, 10.2 g, 13.4 g).
MIMS Class
ATC Classification
J05AR02 - lamivudine and abacavir ; Belongs to the class of antivirals for treatment of HIV infections, combinations.
Presentation/Packing
Form
Kivexa FC tab
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in